✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Shukra Pharmaceuticals Ltd.

SHUKRAPHAR

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹1,570 Cr.
P/E
155.18

Shukra Pharmaceuticals Ltd.

  • Shukra Pharma
  • Bajaj Healthcare
  • Syncom Formulations

FAQs on Shukra Pharmaceuticals Ltd. Shareprice

Shukra Pharma has given better returns compared to its competitors.
Shukra Pharma has grown at ~72.68% over the last 9yrs while peers have grown at a median rate of 10.83%

Yes, Shukra Pharma is expensive.
Latest PE of Shukra Pharma is 152, while 3 year average PE is 73.21.
Also latest EV/EBITDA of Shukra Pharma is 115 while 3yr average is 27.44.

View FAQ's On Business

Growth Table

  • Shukra Pharmaceuticals Ltd.
  • Bajaj Healthcare
  • Syncom Formulations

Balance Sheet

  • Shukra Pharmaceuticals Ltd.
  • Bajaj Healthcare
  • Syncom Formulations

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Shukra Pharmaceuticals Ltd.
  • Bajaj Healthcare
  • Syncom Formulations

Cash Flow

  • Shukra Pharmaceuticals Ltd.
  • Bajaj Healthcare
  • Syncom Formulations

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Shukra Pharmaceuticals Ltd.
  • Bajaj Healthcare
  • Syncom Formulations

Quarterly Results

  • Shukra Pharmaceuticals Ltd.
  • Bajaj Healthcare
  • Syncom Formulations

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Shukra Pharmaceuticals Ltd. Financials

Balance sheet of Shukra Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Shukra Pharma is increasing.
Latest net debt of Shukra Pharma is -₹7.94 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹16.64 Crs.

The profit is oscillating.
The profit of Shukra Pharma is ₹10.12 Crs for TTM, ₹18.54 Crs for Mar 2024 and ₹4.41 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Shukra Pharma latest dividend payout ratio is 5.9% and 3yr average dividend payout ratio is 6.92%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech